Powered by Business Wire
Search Results for Topix.net

Retrophin to Report Second Quarter 2014 Financial Results

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) announced today that it will report its second quarter 2014 financial results on Tuesday, August 12, 2014. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.

Conference Call Information

Date:   Tuesday, August 12, 2014
Time: 8:30 a.m. ET
Dial-in numbers: +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)
Confirmation code: 84497914
Live webcast:

www.retrophin.com in the “Events & Presentations” section of the “Investors” page

 

A replay of the call will be available 11:30 a.m. ET, August 12, 2014 to 11:59 p.m., August 19, 2014. The replay number is 855-859-2056 (U.S.) or 404-537-3406 (International), confirmation code 84497914.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's marketed products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, autism, infantile spasms, nephrotic syndrome and others. Retrophin intends to reintroduce Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.

Contacts

Retrophin, Inc.
Marc Panoff, CFO
646-564-3671
marc@retrophin.com